SUMMARY
The ability of Pseudomonas aeruginosa purified lectin vaccine to protect ICR mice against lethal infection caused by various serotypes of this bacterium was examined. Intraperitoneal injection of the lectin preparation was effective in full protection of the mice against the homologous strain. It was also effective in conferring from a partial to a full protection against most of the other virulent strains tested. The only strain which was still lethal for the immunized mice was one which produces exotoxin A but not lectins.
INTRODUCTION
Despite the availability of potent antibiotics, the mortality from Pseudomonas aeruginosa infections remains a major medical problem due to the multiple drug resistance of this bacterium [1] . Since certain individuals have an essentially high risk for infection with Pseudomonas, there is a growing interest in the development of a vaccine against it [1] [2] [3] . Various antigenic preparations have been
Correspondence to: N. Gilboa-Garber, Department of Life Sciences, Bar-Ilan University, Ramat-Gan 52100, Israel. used as potential P. aeruginosa vaccines. These include LPS [4] , endotoxin protein [5] , exotoxin [6] 'slime' polysaccharides [7] 'slime' glycolipoprotein [8] , cell wall extracts [9] , membrane proteins [10] , proteoids (protease-elastase) [11] , flagella [12] , pill [13] and ribosomal [3] as well as other preparations [1] [2] [3] . Most of these preparations were found to significantly reduce the incidence of animal mortality due to Pseudomonas infection, some of them without and others with visible deleterious side-effects [1] [2] [3] as well as varying degrees of success in coping with the variability of the serotypes involved in the Pseudomonas infections [1-31. We have described the use of P. aeruginosa lectins (PA-I, which reacts with D-galactose and its derivatives and PA-II which reacts with Lfucose, L-galactose and D-mannose) as a vaccine for active and passive immunization of mice against the homologous live pathogenic bacterium [14] . These lectins which are present in extracts of most P. aeruginosa strains resemble the classical plant lectins in their sugar specificity and biophysical properties as well as in exhibiting relative resistance to heating and proteolytic enzymes [15, 16] .
The purpose of the present study was to examine the cross protection of the Pseudomonas lectin vaccine against heterologous serotypes of the bacterium. The results presented in this communication indicate that immunization with the Pseudomonas lectins protects mice, fully against homologous and, fully or partially against most of the heterologous P. aeruginosa strains examined.
MATERIALS AND METHODS

Bacteria
All the P. aeruginosa strains used were hospital isolates. The pyocyanin-producing Pseudomonas ATCC strain No. 33347 of serotype 1 according to Habs [17] which was used for the lectin production and for animal injections was isolated from a patient in the Ichilov Municipal Hospital, TelAviv. ATCC strain No. 29260 (Liu PA-103), was purchased from the ATCC. Habs serotypes 1, 3, 4, 6, 7, 8, 9, 10, 11 and 12, were kindly provided to us by Prof. D. Sompolinsky, Department of Microbiology, Assaf Harofe Hospital, Zrifin, Israel.
Animals
ICR white mice, 17-30 g (male or female), were used for the vaccinations.
Lectin determination
Lectin activity in the extracts of the different strains was examined by a hemagglutination test using papain-treated human erythrocytes [15] .
Purified lectin preparations (PLP)
The source for the purified lectin preparations was P. aeruginosa ATCC strain No. 33347 which is an especially good lectin producer. The purification procedure was previously described [15] . Before injection to the animals the PLP was dialysed against saline for 3 h.
Animal immunization
For active immunization of the mice, the intraperitoneal (i.p.) route was used. It consisted of 2 (five days apart) i.p. injections of PLP (0.2 ml containing 0.18 mg protein).
6. Challenge of the mice
As a challenge, 0.2 ml of a live P. aeruginosa suspension containing 2 x 108 bacteria was injected i.p. to the mice 2-3 days after the second immunization. The mice were observed daily during 2 weeks following the challenge (generally most of the sensitive mice died within 24 h). 
RESULTS
The use of PLP for active immunization was found to be very effective in protecting mice against the homologous pathogenic bacteria. As may be seen from Table 1 all of the non-vaccinated control mice preinjected with saline were dead within 20-48 h after the challenge while all the mice actively immunized with PLP by the i.p. route survived. No visible deleterious side-effects were observed during the 2 weeks follow-up of the mice. Those which were immunized against PLP have also attained varying degrees of protection against challenge by most of the heterologous P. aeruginosa strains examined (Table 1 ) except for the strain ATCC No. 29260, which exhibited no lectin activity (Table 1) .
DISCUSSION
The lectins of P. aeruginosa differ from fimbrial hemagglutinins of enteric bacteria in their location [18] . Only slight lectin activity was shown on the surface of intact P. aeruginosa cells, while significantly higher activities were detected in the periplasmic and more internal spaces [18] . The results obtained in the present study (Table 1) demonstrate the ability of i.p. injection of PLP to induce full protection in mice against lethal infection with the homologous strain. This protection was similar to that attained in mice which survived after injection of 2 x 10 6 live bacteria [14] . The abihty of the PLP vaccine to cross-protect mice against most of the heterologous P. aeruginosa strains examined (Table 1) is an additional indication of its potential value. The only strain which overcame the immunization was that of Liu, PA-103, which produces exotoxin A but not protease [19] . The strain was shown by us to lack lectins (Table 1) .
Thus, with all the points considered, the results presented in this communication suggest that PLP is usable as an efficient vaccine for protection of sensitive animals against infections caused by several serotypes of P. aeruginosa. The possibility that a combined PLP vaccine from several P. aeruginosa strains would further expand the vac-315 cine spectrum to accord with clinical needs is now under investigation.
